29 results about "Enzyme-linked immunosorbant assay" patented technology

Described herein are methods and kits for the detection of platelet-activating pathogenic antibodies in samples from patients suspected of having platelet-activating antibodies or non-HIT anti-PF4 antibody mediated syndromes using platelets and polyvinyl sulfonate or salts thereof. Upon platelet activation, thrombospondin-1 (TSP1), a platelet granule protein, is released and can be detected using a TSP1 antigen capture enzyme linked immunosorbent assay (ELISA) to accurately measure platelet activation.

The invention discloses a method for reducing the allergenicity of bitter almond protein by fermentation with plant lactobacillus, and belongs to the field of food processing. The invention uses bitter almond as raw material, and uses plant lactobacillus FSB7 activated and expanded for fermentation. After fermentation, the free amino acid content of the sample increases by more than 4 times, and the degree of hydrolysis reaches 82%. The optimal fermentation conditions are: bitter almond: water = 1: 20 (w / v), the amount of inoculated liquid is liquid: bitter almond = 0.1% (v / w), the initial pH of fermentation is 6.5, and the fermentation time is 36h. Under such conditions, bitter almond protein can be effectively hydrolyzed, the allergen is destroyed, the allergenicity of bitter almond protein is reduced, and the reduction of the immunogenicity of bitter almond milk is verified by enzyme-linked immunosorbent assay (ELISA). The result shows that the immunogenicity of the fermented bitter almond milk is reduced to about 29% of the original.

The invention discloses an exosome surface protein NELISA (nuclease-linked immunosorbent assay) detection method based on monatomic catalyst activity regulation, and belongs to the technical field of biomedical detection. Compared with a commercial ELISA kit, the exosome surface protein NELISA detection method based on monatomic catalyst activity regulation has the advantages that the linear range of exosome surface protein detection is wider, the exosome detection requirements from low concentration to high concentration can be met, and the method is suitable for more diversified sample types and clinical application scenes; the detection limit is lower, exosomes with lower concentration can be detected, and the kit is suitable for early disease diagnosis and detection of exosome low-abundance samples; the aptamer and the nano material are used for replacing an expensive primary antibody and an enzyme-labeled secondary antibody, so that the reagent cost is remarkably reduced, the method is suitable for popularization and application in areas with limited resources, the economic threshold of exosome detection is reduced, and the method has a good application prospect.

The invention discloses a monoclonal antibody capable of simultaneously identifying mycobacterium tuberculosis secretory protein 64 of a wild type (W-MPT64) and a 63bp deletion mutant type (D-MPT64). The amino acid sequences of variable regions of a heavy chain and a light chain of the antibody are shown as SEQ ID NO.1 and SEQ ID NO.5. The lowest detection limits of W-MPT64 and D-MPT64 by a mycobacterium tuberculosis MPT64 double-antibody sandwich enzyme-linked immunosorbent assay and a fluorescence immunochromatography assay established by using the monoclonal antibody both reach 1.5625 pg / mL, which are significantly higher than the lowest detection limit in the prior art, and the monoclonal antibody can be used for qualitative and quantitative detection of mycobacterium tuberculosis secretory protein 64.

The present invention relates to a polypeptide derived from natural tridegin by structural modification, which may serve as an inhibitor of plasma coagulation factor XIIIa, and to pharmaceutical compositions comprising such polypeptide. The present invention further refers to such polypeptide or pharmaceutical composition for use in a method for treating or preventing a thrombotic event in a patient. Moreover, the invention relates to an endoprosthesis or an enzyme-linked immunosorbent assay (ELISA) plate coated with a polypeptide of the present invention. Furthermore, the invention also encompasses a recombinant fusion protein comprising this polypeptide linked to a fibrinolytic enzyme such as streptokinase, nattokinase or tPAs via a flexible peptide linker containing a thrombin-cleavable site. This construct allows selective inhibition of FXIIIa within a thrombus, while enabling thrombin-triggered release of the fibrinolytic enzyme to induce localized fibrinolysis, thereby achieving targeted dual-action thrombolytic therapy.

The invention discloses a polymer nano-enzyme as well as a preparation method and application thereof. The nano-enzyme comprises a nano-enzyme core modified by a surface modifier and a dendritic polymer coupled with the surface modifier. The preparation method of the polymer nano-enzyme comprises the following steps: preparing a nano-enzyme precursor, and then washing the nano-enzyme precursor to obtain a first intermediate; the nano-enzyme precursor is a nano-enzyme core modified by a surface modifier; preparing a first intermediate dispersion liquid, and adding an activator dispersion liquid and a stabilizer dispersion liquid into the first intermediate dispersion liquid to obtain an activation system; the invention also discloses an application of the polymer nano-enzyme. The polymer nano-enzyme provided by the invention can be used as an enzyme label substitute to be widely applied to enzyme-linked immunosorbent assay, immunohistochemistry, immunochromatography, chemiluminescence and other biochemical detection methods, and signal amplification with high sensitivity, wide pH and high temperature tolerance is realized.

A disposable bioassay diagnostic cartridge for performing enzyme-linked immunosorbent assay for a single patient in whole blood and plasma where the cartridge has a plurality of wells. The cartridge includes a pipette tip with internal sidewalls disposed in one well of the plurality of wells, the internal sidewalls being pretreated and coated with antibodies, a reagent mixture disposed in another well of the plurality of wells, the reagent mixture comprising at least one reagent selected from the group consisting of pH stabilizer, ionic catalyst control agent, ionic intracellular inhibitory control agent, detergent, negative control agent, chelating agent, and biocide preservative, antibody, and conjugate stabilizing agent. At least a chromogenic substrate and visualizing reagent disposed in an integrated cuvette of the plurality of wells. It also includes the detection of the hemoglobin amount in the blood sample so a correction for plasma amount in a sample can be performed.

The invention relates to a method for evaluating the biological value of mesenchymal stem cells, and belongs to the technical field of biology. The method comprises the following steps: firstly, respectively collecting conditioned culture media of mesenchymal stem cells from different donor sources and mesenchymal stem cells expressed by silence TSP2, and detecting the concentration of TSP2 in the culture media by adopting an enzyme-linked immunosorbent assay method; furthermore, inflammatory factors are used for inducing cartilage cells, a conditioned culture medium is replaced for culture for 24 h, then the cells are collected, messenger RNA (mRNA) expression change of II-type collagen of the cells is detected, and the correlation between the TSP2 concentration of the conditioned culture medium and the mRNA expression abundance of the II-type collagen of the cartilage cells is established; the TSP2 concentration in the mesenchymal stem cell culture supernatant is measured, the TSP2 concentration can be used for evaluating the biological value of the mesenchymal stem cells in cartilage regeneration and protection in treatment of osteoarthritis and other degenerative diseases, and a reliable basis is provided for standardization and quality control of mesenchymal stem cell treatment.

The present invention provides a method for making an ELISA plate for paper-based enzyme-linked immunosorbent assay, comprising the following steps: preparing a paper microplate, the surface of which forms a plurality of hydrophobic regions, each of which surrounds a hydrophilic region; immersing the prepared paper microplate in a sodium periodate solution, and dropping a chitosan solution to each hydrophilic region on the paper microplate after taking it out, to form a sodium periodate-chitosan modified layer; then dropping a coated antibody solution to each hydrophilic region, and then dropping a bovine serum albumin solution to each hydrophilic region to form a closed layer, to obtain an ELISA plate. The method for making the ELISA plate enables the coated antibody solution to be connected to the sodium periodate-chitosan modified layer by chemical crosslinking, forming a coated antibody layer fixed on the surface of the hydrophilic region of the paper microplate, enhancing the stability and effectiveness of the fixed coated antibody layer, improving the sensitivity of the p-ELISA method and having good repeatability.

This invention discloses a monoclonal antibody against Oit3 protein in mouse hepatic sinusoidal endothelial cells or its antigen-binding fragment and its applications, belonging to the fields of biotechnology and medical immunology. The monoclonal antibody or its antigen-binding fragment comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region contains HCDR1, HCDR2, and HCDR3 with amino acid sequences as shown in SEQ ID NO. 3~SEQ ID NO. 5; the light chain variable region contains LCDR1, LCDR2, and LCDR3 with amino acid sequences as shown in SEQ ID NO. 8~SEQ ID NO. 10. This monoclonal antibody and the recombinant fluorescent antibody exhibit high affinity and high specificity, and can be effectively applied to enzyme-linked immunosorbent assay (ELISA), Western blotting, and immunofluorescence detection. They can serve as important antibody tools for basic research on mouse hepatic sinusoidal endothelial cells and for exploring the mechanisms of liver diseases. Based on its variable region sequence, a recombinant fluorescent antibody, Oit3-scFv-GFP, was also constructed. This recombinant fluorescent antibody enables one-step direct immunofluorescence staining, providing a convenient tool for in situ visualization of mouse hepatic sinusoidal endothelial cells.

The invention discloses a litopenaeus vannamei Vg polyclonal antibody as well as a preparation method, a quantitative detection method and application thereof, and relates to the field of biotechnology and immunodetection. The polyclonal antibody is obtained by immunizing a polypeptide antigen containing an amino acid sequence SEQ ID NO: 1 (CPTKYEIETEGEKV), and the polyclonal antibody can specifically recognize the litopenaeus vannamei Vg. The invention provides and establishes a novel non-double antibody sandwich enzyme-linked immunosorbent assay (ELISA) method for the first time, and the core of the novel non-double antibody sandwich enzyme-linked immunosorbent assay (ELISA) method is that a Litopenaeus vannamei VgR ligand binding structural domain is used as a solid-phase capture molecule, and the polyclonal antibody is used as a detection antibody to form a receptor-ligand-antibody detection mode. The method effectively avoids the technical bottleneck that paired antibodies are difficult to prepare in a traditional method, and has the advantages of wide linear range and good repeatability.

Glycan-binding proteins, and compositions thereof, are generally described, including methods of making and using such proteins. The proteins may include scaffolds based on easily evolvable DNA-binding proteins, with binding sites able to specifically bind to mono- or disaccharides, such as monosaccharide-binding determinants, disaccharide-binding determinants, more complex carbohydrates, etc. In certain aspects, a protein may be generated starting from a small DNA-binding protein, such as Sso7d. Such glycan-binding proteins may have numerous applications, including in enzyme-linked immunosorbent assays (ELISAs), glycan characterization, cell selection, flow cytometry, histology, imaging, arrays, affinity purification, enzyme-linked visualization, binding to a target for pharmaceutical purposes, etc.

This disclosure provides methods for identifying a subject suitable for an adeno associated vims (AAV) therapy. In some embodiments, the method comprises measuring a titer of an antibody or antigen-binding portion thereof that specifically binds to an AAV (“anti-AAV antibody”) in a biological sample obtained from the subject using an enzyme-linked immunosorbent assay (ELISA).

The invention discloses a method for detecting cucumber green mottle mosaic virus (CGMMV) in soil aiming at the detection technical requirements of important plant pathogens in the soil. The method comprises the following steps: sampling to-be-detected field soil, adding clear water with the same weight, stirring until soil particles are uniform, standing, filtering supernatant liquid, adding polyethylene glycol (the molecular weight is 6000-8000, and the final concentration is 6-10%) and sodium chloride (the final concentration is 1-2%), carrying out ice bath treatment for 2 hours to overnight, centrifuging 12000 g of the solution for 1 hour to settle virus particles, and dissolving and precipitating with distilled water to obtain virus-enriched liquid; the CGMMV can be directly detected by using various conventional detection methods, including an RT-PCR (Reverse Transcription-Polymerase Chain Reaction) method, a fluorescent quantitative PCR method, a colloidal gold immunochromatography method, enzyme-linked immunosorbent assay (ELISA) and the like. According to the method, on the premise of ensuring the reliability and the accuracy, the detection steps are simplified, and the cost and the time are saved. The method is applied to detection of the CGMMV in soil of a cucurbitaceae crop planting field, can effectively guide disease prevention and control in production, and prevents diffusion and harm of the CGMMV.

The present invention discloses a hapten for detecting toxoflavin, and an artificial antigen and antibody for detecting toxoflavin are prepared based on the hapten. The hapten completely retains the structural characteristics of toxoflavin, and the artificial antigen prepared by the hapten has an intact structure and completely retains the original characteristics of toxoflavin, which is conducive to presenting the structural characteristics of toxoflavin and improving the immunogenicity of the artificial antigen. The artificial antigen can quantitatively detect toxoflavin in a sample to be tested. When used in enzyme-linked immunosorbent assay (ELISA) of toxoflavin, IC 50 The value is 0.41μg / L; at the same time, based on the artificial antigen, an immunochromatographic test strip for the quantitative detection of toxoplasmone is provided. The detection sensitivity of toxoplasmone standard reaches 0.1μg / L, and the detection limit of toxoplasmone in the test sample reaches 25ng / kg, which can achieve high-sensitivity detection of toxoplasmone.

A protein detection method and a detection device as well as use are provided. The protein detection method includes: fixing a probe type graphic encoding chip coupled with a specific capture antibody in the detection device, and meanwhile respectively sealing SAPE and a detection antibody in the detection device; and when in detection, performing detection and analysis based on an enzyme linked immunosorbent assay (ELISA) principle through the probe-type graphic encoding chip after the detection antibody and the SAPE are respectively dissolved, so as to obtain protein quantitative analysis results. In the protein detection method, the adopted Lab-in-Tip technology can complete processes such as sampling, washing, detection antibody hybridization, washing and binding of fluorescence labeled streptavidin and a biotin labeled detection antibody in such the Lab-in-Tip device, and has the advantages of multiplexed detection, such as quick completion, convenience, high flexibility, good specificity, few sample capacity and wide detection range.

This disclosure provides methods for identifying a subject suitable for an adeno associated virus (AAV) therapy. In some embodiments, the method comprises measuring a titer of an antibody or antigen-binding portion thereof that specifically binds to an AAV (“anti-AAV antibody”) in a biological sample obtained from the subject using an enzyme-linked immunosorbent assay (ELISA).

The present invention discloses a droplet digital enzyme-linked immunosorbent assay method, device and related medium, the method comprising: obtaining a droplet image; identifying the droplet image by deep learning technology to obtain all droplets in the droplet image and the number of magnetic beads contained in each droplet; classifying the droplets according to the number of magnetic beads to obtain multiple droplet types; for the target droplets in each droplet type, statistically obtaining the positive probability and negative probability of the target droplet; based on the positive probability and negative probability, constructing a Poisson distribution and likelihood function of the average enzyme on the magnetic beads, obtaining the number of the average enzyme according to the Poisson distribution and likelihood function, and then outputting the number of the average enzyme as a measurement result. The present invention uses Poisson distribution and likelihood function to perform statistical analysis on different types of droplets, which can improve the accuracy and applicability of the analysis and test results of the enzyme-linked immunosorbent assay, thereby reducing the difficulty of downstream analysis.

The utility model relates to the technical field of elisa batten injection molds, and provides an elisa batten injection mold which at least comprises a mold cavity used for injection molding of an elisa batten; the pouring gate is arranged at the position, corresponding to the edge of the bottom of the reaction hole of the elisa plate strip, of the mold cavity, so that after injection molding materials for injection molding enter the mold cavity through the pouring gate, a cavity corresponding to the bottom of the elisa plate strip is filled with the injection molding materials, and then the injection molding materials are filled from the cavity corresponding to the bottom of the elisa plate strip to the cavity corresponding to the opening of the elisa plate strip. According to the elisa strip injection mold, it can be ensured that glue is fully injected into the bottom of an elisa strip, so that the elisa strip with the smooth and flat hole bottom is obtained, the position where herringbone flow lines are formed or the position where the flatness is poor is located at the opening of the elisa strip, the position does not involve the enzyme-linked immunosorbent assay (ELISA) reaction, the result is not affected, and the inter-hole CV value is not affected either.

The application belongs to the technical field of detection and analysis, and particularly relates to a method for detecting anti-PEG-EPO drug-resistant antibodies based on electrochemiluminescence and application thereof. The application successfully detects anti-PEG-EPO drug-resistant antibodies in human serum by using electrochemiluminescence MSD technology for the first time. Compared with existing enzyme-linked immunosorbent assay methods, the detection method is simple, easier to operate, greatly shortens the detection time, significantly improves the experimental efficiency, has high detection sensitivity, strong specificity, good method robustness, and therefore has good practical application value.

The application discloses a kind of simultaneously identifying wild type (W-MPT64) and 63bp deletion mutant (D-MPT64) Mycobacterium tuberculosis secreted protein 64 monoclonal antibody.The antibody heavy chain and light chain variable region amino acid sequence as shown in SEQ ID NO.1 and SEQ ID NO.5.The Mycobacterium tuberculosis MPT64 double antibody sandwich enzyme-linked immunosorbent assay and fluorescence immunoassay method established using the monoclonal antibody reach 1.5625 pg / mL, significantly higher than the minimum detection limit of prior art, can be used for qualitative and quantitative detection of Mycobacterium tuberculosis secreted protein 64.

The utility model discloses an enzyme linked immunosorbent assay kit convenient for rapid detection, which comprises a first kit, one side of the first kit is provided with a second kit, the outer side surface of the second kit is provided with an assembling groove, and the outer side surface of the first kit is fixedly provided with an assembling strip. The internal structures of the first kit and the second kit are consistent. According to the enzyme-linked immunosorbent assay kit convenient for rapid detection, when reagent bottles in the first kit and the second kit are placed, the two groups of splicing strips on the first kit are inserted into the two groups of splicing grooves in the outer side of the second kit, so that the first kit and the second kit can be combined into a whole; a large number of kits are assembled together, so that the stability during transportation is ensured, collision caused by toppling is avoided, and a large number of reagent bottles in the kits are protected.

The invention discloses an external medicine for preventing and / or treating eczema. The external medicine is mainly prepared from purslane, golden cypress, mint, folium isatidis, angelica sinensis, raw liquorice, fructus kochiae, radix sophorae flavescentis, gypsum rubrum and coptis chinensis. A mouse eczema model induced by 2, 4-dinitrochlorobenzene (DNCB) is adopted, a positive drug compound dexamethasone acetate emulsifiable paste and different doses of the externally-applied drug are externally applied to the skin, and the treatment effect of the externally-applied drug on eczema mice is observed. Experimental results show that after administration intervention, compared with a model group, the skin lesion condition of mice in each administration group is obviously improved, the ear swelling degree is reduced, the organ index is reduced, the skin inflammatory infiltration is relieved, and the difference has statistical significance. An enzyme-linked immunosorbent assay (ELISA) result shows that compared with a model group, each dose group of the external medicine can reduce the levels of interleukin 4 (IL-4), gamma-interferon (IFN-gamma), immune globulin E (IgE) and IL-4 / IFN-gamma in mouse serum to different degrees, and the difference has statistical significance.

The invention provides application of ARG2 as a biomarker in preparation of a sepsis early diagnosis product, and belongs to the field of medical diagnosis. Specifically, according to the technical scheme, the ARG2 level of serum is detected by adopting an ELISA method, an elisa kit is used, qualitative or quantitative analysis is carried out according to the color depth, and whether a patient is infected with sepsis or not can be effectively diagnosed. The serum ARG2 is applied to early diagnosis of sepsis for the first time, and the detection method has the advantages of high sensitivity, high specificity, simplicity, convenience and rapidness in operation and the like, is low in price and is suitable for popularization and application.

The application discloses arylpiperazine salt compounds, a synthesis method thereof and application thereof in antidepressants, and belongs to the field of medicinal chemistry. The arylpiperazine salt compounds containing bioactivity are obtained through a plurality of continuous reactions such as N-alkylation, protection of a group, condensation and deprotection, etc. of arylpiperazine as raw material. Researches show that the compounds exhibit high receptor binding of 5-HT 2A R and GABA A Rs. The target points are confirmed through molecular docking, micro-thermal mobility instrument, surface plasmon resonance, inositol-phosphoric acid (IP1) accumulation and cell membrane patch clamp, etc.; and the anti-inflammatory activity of the compounds is evaluated by enzyme-linked immunosorbent assay, so as to provide a potential active structure skeleton for development of antidepressants.

The invention belongs to the technical field of molecular biology, and relates to a biomarker for predicting altitude stress susceptibility and application of the biomarker. The biomarkers for predicting the altitude stress susceptibility comprise RBM39, MSLN and LILRA2, and whether a subject is a plateau population or a non-high-reflectivity population is judged by detecting the expression quantity of the protein markers in fresh urine of the subject. According to the biomarker detection provided by the invention, whether an individual has altitude stress or not can be predicted in advance only through a urine sample collected in a non-invasive manner, so that the method is completely painless, and meanwhile, a large amount of time and economic expenditure for performing field test at high altitude are saved. The biomarker provided by the invention can be detected through a proteomics technology, a protein immunoblotting analysis technology or an enzyme-linked immunosorbent assay technology, and the detection efficiency is high, so that a detection service or a detection kit convenient for practical application can be formed; and a clear and accurate basis is provided for advanced prediction and adaptive stroke design of altitude stress.

Disclosed herein are compositions, methods, devices, and systems for detection of T1D autoantibodies. Bridging complexes for use in enzyme-linked immunosorbent assays (ELISAs) are disclosed. The bridging complexes can be used to detect insulin autoantibodies (lAAs) in human and animal blood or serum. The disclosed compositions, methods, devices, and systems can form complexes between a biotin-labeled proinsulin molecule, an TAA, and a dinitrophenol (DNP)-labeled proinsulin molecule.

Disclosed here is a device and method to detect the presence or absence of a target molecule by detecting fluorescence resonance energy transfer (FRET) signal generated when two labeled probes bind to the target molecule. The method is a sandwich enzyme-linked immunosorbent assay (ELISA) or a nucleic acid hybridization assay.

The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.